Linkedin
Sign in
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Type here...
Search
Home
About
Editor’s Corner
Contribute
Contact Us
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner
Instagram
Linkedin
Twitter
Subscribe
Subscribe
Wednesday, March 25, 2026
25.9
C
Bengaluru
Home
About
Editor’s Corner
Contribute
Contact Us
My account
Get into your account.
Login
Register
type here...
Search
Facebook
Linkedin
Twitter
Youtube
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
The ₹5 Snack SKU: A Silent Indian Metabolic Crisis
0
Executive Summary — The Paradox of Scale In the annals...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Does Public-Private Partnership Benefit The Public?
0
Does This Public-Private Partnership Benefit The Public?” (Tuesday, July...
Interesting, Engaving & Relevant
0
In this issue Deepak Sharma talks about his journey from Medical Rep to Country Manager. Deeksha Fouzdar presents a case study on implementation of a competency-based HR system in Pharma. Other articles by K. Hariram and Vivek Hattangadi
Nutraceuticals: Health, Hope Or Hype?
0
Walk into almost any clinic today and you will...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Marketing
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Policies/Sales
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Strategy
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Subscribe
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
0
A recent industry spotlight by Venkat Mutavi notes a...
Is Telemedicine Here to Stay?
0
9 million people used telemedicine services during the early...
Analysis of the Fastest Growing Companies and Therapy Areas in IPM – MAT Dec’24
0
Growth Performance of Top 50 Companies in IPM (MAT...
India’s Patent Revocations: Strengthening Access and Challenging Evergreening
0
The Indian Patent Office’s recent decision to revoke Novartis’...
Digital in Health – Making Healthcare Patient Centric
0
Interview with Hanno Wolfram, author of Digital in Health Anup...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Marketing
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Policies/Sales
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Strategy
Razumab at 11: A Decade of Disruption, Safety Lessons, and the New Biosimilar Reality
0
Abstract When Intas Pharmaceuticals launched Razumab in June 2015 as...
Healthcare and Gulf War: When Elephants Fight, the Grass Gets Trampled
0
From Gas Cylinders to ICU Beds: How the Gulf...
Semaglutide: Just Another Off-Patent Generic? Or a Different Beast Entirely?
0
As over 50 generic versions of the blockbuster weight-loss...
Excellence or Mediocrity—What Are You Building?
0
Excellence is a choice. So is Mediocrity Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
0
In the blistering Sonoran Desert, where temperatures regularly exceed...
Subscribe
man2